Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT

Zachariah DeFilipp, Rafael F. Duarte, John A. Snowden, Navneet S. Majhail, Diana M. Greenfield, José López Miranda, Mutlu Arat, K. Scott Baker, Linda J. Burns, Christine N. Duncan, Maria Gilleece, Gregory A. Hale, Mehdi Hamadani, Betty K. Hamilton, William Hogan, Jack W. Hsu, Yoshihiro Inamoto, Rammurti T. Kamble, Maria Teresa Lupo-Stanghellini, Adriana K. MalonePhilip McCarthy, Mohamad Mohty, Maxim Norkin, Pamela Paplham, Muthalagu Ramanathan, John M. Richart, Nina Salooja, Harry C. Schouten, Helene Schoemans, Adriana Seber, Amir Steinberg, Baldeep M. Wirk, William A. Wood, Minoo Battiwalla, Mary E.D. Flowers, Bipin N. Savani, Bronwen E. Shaw

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31% to 49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to review literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

Original languageEnglish (US)
Pages (from-to)1493-1503
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number8
DOIs
StatePublished - Aug 1 2016

Fingerprint

Metabolic Diseases
Cell Transplantation
Cardiovascular Diseases
Survivors
Preventive Medicine
Mortality
Diabetes Mellitus
Bone Marrow
Guidelines
Transplants
Incidence
Research

Keywords

  • Cardiovascular disease
  • Hematopoietic cell transplantation
  • Late effects
  • Metabolic syndrome
  • Survivorship

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation : Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. / DeFilipp, Zachariah; Duarte, Rafael F.; Snowden, John A.; Majhail, Navneet S.; Greenfield, Diana M.; Miranda, José López; Arat, Mutlu; Baker, K. Scott; Burns, Linda J.; Duncan, Christine N.; Gilleece, Maria; Hale, Gregory A.; Hamadani, Mehdi; Hamilton, Betty K.; Hogan, William; Hsu, Jack W.; Inamoto, Yoshihiro; Kamble, Rammurti T.; Lupo-Stanghellini, Maria Teresa; Malone, Adriana K.; McCarthy, Philip; Mohty, Mohamad; Norkin, Maxim; Paplham, Pamela; Ramanathan, Muthalagu; Richart, John M.; Salooja, Nina; Schouten, Harry C.; Schoemans, Helene; Seber, Adriana; Steinberg, Amir; Wirk, Baldeep M.; Wood, William A.; Battiwalla, Minoo; Flowers, Mary E.D.; Savani, Bipin N.; Shaw, Bronwen E.

In: Biology of Blood and Marrow Transplantation, Vol. 22, No. 8, 01.08.2016, p. 1493-1503.

Research output: Contribution to journalArticle

DeFilipp, Z, Duarte, RF, Snowden, JA, Majhail, NS, Greenfield, DM, Miranda, JL, Arat, M, Baker, KS, Burns, LJ, Duncan, CN, Gilleece, M, Hale, GA, Hamadani, M, Hamilton, BK, Hogan, W, Hsu, JW, Inamoto, Y, Kamble, RT, Lupo-Stanghellini, MT, Malone, AK, McCarthy, P, Mohty, M, Norkin, M, Paplham, P, Ramanathan, M, Richart, JM, Salooja, N, Schouten, HC, Schoemans, H, Seber, A, Steinberg, A, Wirk, BM, Wood, WA, Battiwalla, M, Flowers, MED, Savani, BN & Shaw, BE 2016, 'Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT', Biology of Blood and Marrow Transplantation, vol. 22, no. 8, pp. 1493-1503. https://doi.org/10.1016/j.bbmt.2016.05.007
DeFilipp, Zachariah ; Duarte, Rafael F. ; Snowden, John A. ; Majhail, Navneet S. ; Greenfield, Diana M. ; Miranda, José López ; Arat, Mutlu ; Baker, K. Scott ; Burns, Linda J. ; Duncan, Christine N. ; Gilleece, Maria ; Hale, Gregory A. ; Hamadani, Mehdi ; Hamilton, Betty K. ; Hogan, William ; Hsu, Jack W. ; Inamoto, Yoshihiro ; Kamble, Rammurti T. ; Lupo-Stanghellini, Maria Teresa ; Malone, Adriana K. ; McCarthy, Philip ; Mohty, Mohamad ; Norkin, Maxim ; Paplham, Pamela ; Ramanathan, Muthalagu ; Richart, John M. ; Salooja, Nina ; Schouten, Harry C. ; Schoemans, Helene ; Seber, Adriana ; Steinberg, Amir ; Wirk, Baldeep M. ; Wood, William A. ; Battiwalla, Minoo ; Flowers, Mary E.D. ; Savani, Bipin N. ; Shaw, Bronwen E. / Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation : Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. In: Biology of Blood and Marrow Transplantation. 2016 ; Vol. 22, No. 8. pp. 1493-1503.
@article{27b807abdc1841139b8e0e59d18e98e8,
title = "Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT",
abstract = "Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31{\%} to 49{\%} among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to review literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.",
keywords = "Cardiovascular disease, Hematopoietic cell transplantation, Late effects, Metabolic syndrome, Survivorship",
author = "Zachariah DeFilipp and Duarte, {Rafael F.} and Snowden, {John A.} and Majhail, {Navneet S.} and Greenfield, {Diana M.} and Miranda, {Jos{\'e} L{\'o}pez} and Mutlu Arat and Baker, {K. Scott} and Burns, {Linda J.} and Duncan, {Christine N.} and Maria Gilleece and Hale, {Gregory A.} and Mehdi Hamadani and Hamilton, {Betty K.} and William Hogan and Hsu, {Jack W.} and Yoshihiro Inamoto and Kamble, {Rammurti T.} and Lupo-Stanghellini, {Maria Teresa} and Malone, {Adriana K.} and Philip McCarthy and Mohamad Mohty and Maxim Norkin and Pamela Paplham and Muthalagu Ramanathan and Richart, {John M.} and Nina Salooja and Schouten, {Harry C.} and Helene Schoemans and Adriana Seber and Amir Steinberg and Wirk, {Baldeep M.} and Wood, {William A.} and Minoo Battiwalla and Flowers, {Mary E.D.} and Savani, {Bipin N.} and Shaw, {Bronwen E.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.bbmt.2016.05.007",
language = "English (US)",
volume = "22",
pages = "1493--1503",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation

T2 - Screening and Preventive Practice Recommendations from the CIBMTR and EBMT

AU - DeFilipp, Zachariah

AU - Duarte, Rafael F.

AU - Snowden, John A.

AU - Majhail, Navneet S.

AU - Greenfield, Diana M.

AU - Miranda, José López

AU - Arat, Mutlu

AU - Baker, K. Scott

AU - Burns, Linda J.

AU - Duncan, Christine N.

AU - Gilleece, Maria

AU - Hale, Gregory A.

AU - Hamadani, Mehdi

AU - Hamilton, Betty K.

AU - Hogan, William

AU - Hsu, Jack W.

AU - Inamoto, Yoshihiro

AU - Kamble, Rammurti T.

AU - Lupo-Stanghellini, Maria Teresa

AU - Malone, Adriana K.

AU - McCarthy, Philip

AU - Mohty, Mohamad

AU - Norkin, Maxim

AU - Paplham, Pamela

AU - Ramanathan, Muthalagu

AU - Richart, John M.

AU - Salooja, Nina

AU - Schouten, Harry C.

AU - Schoemans, Helene

AU - Seber, Adriana

AU - Steinberg, Amir

AU - Wirk, Baldeep M.

AU - Wood, William A.

AU - Battiwalla, Minoo

AU - Flowers, Mary E.D.

AU - Savani, Bipin N.

AU - Shaw, Bronwen E.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31% to 49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to review literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

AB - Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31% to 49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to review literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.

KW - Cardiovascular disease

KW - Hematopoietic cell transplantation

KW - Late effects

KW - Metabolic syndrome

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=84981340623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981340623&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.05.007

DO - 10.1016/j.bbmt.2016.05.007

M3 - Article

C2 - 27184625

AN - SCOPUS:84981340623

VL - 22

SP - 1493

EP - 1503

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 8

ER -